Killer cell immunoglobulin-like receptor 2DL2

Canonical identity and biological annotation from UniProt.

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.